Melanoma Therapeutics Market 2020 - Industry Analysis and Forecast by Radiant Insights, Inc.
Summary Radiant Insights, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth" Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas. Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth. Access This Full Report @ http://www.radiantinsights.com/research/melanoma-therapeutics-market-to-2020-rising-prevalence-and-evolving-treatment-algorithms-to-drive-market-growth Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.
Summary
Radiant Insights, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth"
Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas.
Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.
Access This Full Report @ http://www.radiantinsights.com/research/melanoma-therapeutics-market-to-2020-rising-prevalence-and-evolving-treatment-algorithms-to-drive-market-growth
Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Figure 18: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Breakdown of Safety/drug Biochemistry <strong>and</strong> Efficacy<br />
Clinical Trial Primary Endpoints <strong>by</strong> Phase of Development, 2006-2013 93<br />
Figure 19: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Secondary Clinical Trial Endpoints <strong>by</strong> Phase of<br />
Development (%), 2006-2013 94<br />
Figure 20: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Breakdown of Safety/drug biochemistry, Efficacy<br />
<strong>and</strong> 'Other' Clinical Trial Secondary Endpoints <strong>by</strong> Phase of Development, 2006-2013 96<br />
Figure 21: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global Sales <strong>Forecast</strong> for Seviprotimut-L ($m), 2017-<strong>2020</strong><br />
99<br />
Figure 22: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Sales <strong>Forecast</strong> for Yervoy (Adjuvant Setting) ($m),<br />
2016-<strong>2020</strong> 101<br />
Figure 23: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global Sales <strong>Forecast</strong> for Talimogene Laherparepvec (T-Vec)<br />
($m), 2015-<strong>2020</strong> 103<br />
Figure 24: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Sales <strong>Forecast</strong> for Selumetinib ($m), 2016-<strong>2020</strong> 106<br />
Access This Full Report @ http://www.radiantinsights.com/research/melanoma-therapeuticsmarket-to-<strong>2020</strong>-rising-prevalence-<strong>and</strong>-evolving-treatment-algorithms-to-drive-market-growth<br />
Figure 25: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global Sales <strong>Forecast</strong> for Binimetinib ($m), 2016-<strong>2020</strong> 108<br />
Figure 26: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Sales <strong>Forecast</strong> for Cobimetinib ($m), 2015-<strong>2020</strong> 110<br />
Figure 27: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Adjuvant Pipeline Products, 2014 111<br />
Figure 28: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Advanced Pipeline Products, 2014 112<br />
Figure 29: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Heat Map for Advanced Pipeline Products, 2014<br />
(continued) 113<br />
Figure 30: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Competitor Matrix for Advanced Products, 2014 114<br />
Figure 31: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Global, Treatment Patterns ('000) <strong>and</strong> <strong>Market</strong> Size ($bn),<br />
2013-<strong>2020</strong> 118<br />
Figure 32: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, North America, Treatment Patterns, 2013-<strong>2020</strong> 122<br />
Figure 33: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, North America, Annual Cost of Therapy ($), 2013-<strong>2020</strong> 123<br />
Figure 34: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, North America, <strong>Market</strong> Size, 2013-<strong>2020</strong> 125<br />
Figure 35: <strong>Melanoma</strong> <strong>Therapeutics</strong> <strong>Market</strong>, Five EU Countries, Treatment Patterns ('000), 2013-<strong>2020</strong> 126
Change language